Clinical Topics

Melanomas Associated With Internal Malignancy Risk

by U.S. Medicine

January 1, 2019

PALO ALTO, CA — Genetic and environmental risk factors have been associated with the development of multiple primary melanomas (MPM) but a new study questioned whether those patients might have increased predisposition to developing internal malignancies.

The report published in the Journal of the American Academy of Dermatology sought to identify the risk of subsequent malignancies in MPM patients.1

Researchers from the VA Palo Alto, CA, Health Care System and Stanford University Medical Center analyzed multiple primary standardized incidence ratios for patients with one or more, two or more and three or more primary melanomas (PM) in the SEER database from 1973-2014.

Ultimately, they identified 223,799 patients with one or more, 19,709 with two or more and 3,995 with three or more PM, and found that risks of subsequent internal malignancy increased with number of PM, with observed to expected (O/E) ratios of 0.99, 1.14, and 1.23 (p<0.05) for patients with at least one, two and three PM respectively.

The study team reported that Internal malignancy was higher in younger MPM patients and those with superficial spreading melanoma

Most frequent malignancies among MPM patients included breast, prostate, thyroid, soft tissue, brain, kidney, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia. Results indicated that risk of subsequent cutaneous melanoma increased with O/E ratios of 8.09, to 22.52, to 41.03 (p<0.05) respectively.

While limited by incomplete SEER information about pigmentation phenotypes, histology, and treatments, study authors concluded, “Patients with MPM have increased risk of subsequent internal and cutaneous malignancies and may benefit from tight adherence to age-specific cancer screening.”

1. Cai ED, Swetter SM, Sarin KY. Association of multiple primary melanomas with malignancy risk: a population-based analysis of the Surveillance, Epidemiology, and End Results Program database from 1973-2014. J Am Acad Dermatol. 2018 Oct 1. pii: S0190-9622(18)32637-9. doi: 10.1016/j.jaad.2018.09.027. [Epub ahead of print] PubMed PMID: 30287320.


Comments are closed here.


Related Articles

Racial Disparities Found in BRCA Testing, Counseling

DURHAM, NC—Despite increases in BRCA mutation testing, racial/ethnic disparities in counseling and testing have persisted for decades, a study argued. The review published in the Journal of Racial and Ethnic Health Disparities said its purpose... View Article

VA Guideline Addresses Dental Management of Head/Neck Cancer Patients

SAN FRANCISCO—Few protocols have been published for the dental management of patients with head and neck cancer to prevent complications from head and neck radiation therapy, according to a new study.  The report in the... View Article


U.S. Medicine Recommends


More From oncology

Oncology

Racial Disparities Found in BRCA Testing, Counseling

DURHAM, NC—Despite increases in BRCA mutation testing, racial/ethnic disparities in counseling and testing have persisted for decades, a study argued. The review published in the Journal of Racial and Ethnic Health Disparities said its purpose... View Article

Oncology

VA Guideline Addresses Dental Management of Head/Neck Cancer Patients

SAN FRANCISCO—Few protocols have been published for the dental management of patients with head and neck cancer to prevent complications from head and neck radiation therapy, according to a new study.  The report in the... View Article

Oncology

Patients Treated with Thiopurines Have Higher Skin Cancer Mortality

PHILADELPHIA—Treatment with thiopurines is associated with an increased risk of squamous cell carcinoma of the skin in patients with inflammatory bowel diseases. An article in Clinical Gastroenterology and Hepatology discussed results of a study that... View Article

Oncology

Overcoming Radiation Resistant Prostate Cancer

LOS ANGELES—For nearly half of the patients with localized advanced prostate cancer, radiation therapy is the primary intervention and standard of care for recurrent disease following surgery. The problem is that nearly 30% to 50%... View Article

Oncology

JAK Enzymes Can Treat Leukemia, Lymphoma

NASHVILLE, TN—Precision oncology prescribes the use of molecularly-targeted therapy directed by identification of genomic alterations. A new study suggested the approach is particularly applicable to neoplasms that are resistant to standard cytotoxic chemotherapy, such as... View Article

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up